Molibresib (I-BET-762)

Name: Molibresib (I-BET-762)
Brand: Selleck Chemicals
SKU: S7189
Rating: 5 (18 reviews)

For research use only.

Catalog No.S7189 Synonyms: GSK525762, GSK525762A

18 publications

Molibresib (I-BET-762) Chemical Structure

CAS No. 1260907-17-2

Molibresib (I-BET-762, GSK525762, GSK525762A) is an inhibitor for BET proteins with IC50 of ~35 nM in a cell-free assay, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

Selleck's Molibresib (I-BET-762) has been cited by 18 publications

Cancer Discov, 2018, 8(4):458-477

PubMed: 29386193 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1833

PubMed: 32286255 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

EBioMedicine, 2019, 43:201-210

PubMed: 30975544 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):1030-1039

PubMed: 30899402 ( click the link to review the publication )

Leuk Res, 2019, 77:42-50

PubMed: 30642575 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4331-4343

PubMed: 29792310 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Nature, 2016, 534(7607):407-411

PubMed: 27281208 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35753-35767

PubMed: 26840085 ( click the link to review the publication )

2 Customer Reviews

PECAPJ49 parental and cetuximab-resistant clones were treated with 100 nmol/L cetuximab ± 800 nmol/L I-BET-762(IBET) for 72 hours. Cells were stained with crystal violet and quantified as described in Materials and Methods (n = 3; *, P < 0.02). Figures are representative of three independent experiments.

Cancer Res, 2018, 78(15):4331-4343. Molibresib (I-BET-762) purchased from Selleck.
A., B. and C. Dose response curves of MPNST-derived cell lines treated with three bromodomain inhibitors: JQ1, OTX015 and I-BET-762.

Oncotarget, 2016, 7(24):35753-35767. Molibresib (I-BET-762) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description

Targets

BET proteins ^[1]
(Cell-free assay)

35 nM

In vitro

I-BET-762 is an inhibitor for BET (bromodomain and extra terminal domain) proteins, BRD2, BRD3 and BRD4, binds to the tandem bromodomains of BET with K_d of 50.5–61.3 nM, displaces a tetra-acetylated H4 peptide prebound to tandem bromodomains of BET with IC50 of 32.5–42.5 nM in FRET analysis. I-BET-762 occupies the acetyl-lysine binding pocket of BET proteins and inhibits binding of BET proteins to acetylated histones, thus disrupts the formation of the chromatin complexes essential for expression of inflammatory genes. ^[1] I-BET-762 treatment during the first 2 d of differentiation alters CD4⁺ T-cell cytokine production, up-regulated expression of several antiinflammatory gene products and down-regulated expression of several proinflammatory cytokines. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HepG2	M2rl[2Z2dmO2aX;uJIF{e2G7		NV3jWFZnOThiaILz	NI\1S49KdmS3Y4Tpc44hd2ZiaIXtZY4hSXCxQUGg[4Vv\SCneIDy[ZN{cW:wIHnuJJN1[WKueTD0doFve2[nY4Tl[EBpfW2jbjDI[ZBIOiClZXzsd{Bkd2W6cILld5NqdmdibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGGodHXyJFE5KGi{czDifUBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUCgQUAxNjdizszNMi=>	NVTnTGhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1Olg{OjJpPkKxOVY5OzJ{PD;hQi=>
HepG2	NVvMNm1VTnWwY4Tpc44h[XO\|YYm=		NGraOZA3KGi{cx?=	NHPJ[pZKdmS3Y4Tpc44hd2ZiaIXtZY4hSXCxQUGgdJJwfGWrbjDzfY51cGW\|aYOgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNibnXvd5lvfGinc3nz[YQhemGmaX;sZYJmdGWmIIDyc5RmcW5ic3XjdoV1cW:wIHHmeIVzKDZiaILzJIJ6KFOGUzDQRWdGKGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJHs{PVOfbXX0bIlwdmmwZR?=	NH7FNWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW2PFMzOid-MkG1Olg{OjJ:L3G+
HepG2	NVXDToFSTnWwY4Tpc44h[XO\|YYm=		Ml[yNVghcHK\|	M4m0VXVxemWpdXzheIlwdiCxZjDBdI9COSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6lcnXhd4UhPzBnIH;mJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgNVghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVOxO\|AhRSByLkKg{txONg>?	M{\YS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i2OVI6Lz5{MkO4OlUzQTxxYU6=
HepG2	NYCwSod2TnWwY4Tpc44h[XO\|YYm=		Mk\sNVghcHK\|	M2LuUGlv\HWldHnvckBw\iCqdX3hckBCeG:DMTDn[Y5mKGW6cILld5Nqd25iaX6gd5Ri[my7IITyZY5{\mWldHXkJIh2dWGwIFjldGczKGOnbHzzJINw\XiycnXzd4lv\yCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[W[2ZYKgNVghcHK\|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvPyEQvF2u	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{NESzOEc,OjJ7MkS0N\|Q9N2F-
PBMC	M33QSWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?			NUK4S\|JPSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDCUWMh[2WubIOgZZN{\XO\|ZXSgZZMhVFCVLXnu[JVk\WRiSVytOkBxem:mdXP0bY9vKGK7IHPo[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5\|MU[yN{DPxE1w	NXHKWY54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU6PjdpPkK0NFE2QTZ5PD;hQi=>
Raji	MoTxSpVv[3Srb36gZZN{[Xl?		MVW0JIhzew>?	NHHrVFRKdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hWmGsaTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhVVmFIHX4dJJme3Orb36gZYZ1\XJiNDDodpMtKEmFNUCgQUAxNjF7IN88UU4>	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3OVgoRjJ2OUCwO\|U5RC:jPh?=
Rosetta2 DE3	NHHHTphHfW6ldHnvckBie3OjeR?=		NXfNNmZiOzBibXnudy=>	MUnEbZNxdGGlZX3lcpQhd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IH\yc40hSlKGMzDCSFIhMDNyNjD0c{A1OTdiYX3pco8h[WOrZDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkCzNFMh\|ryPLh?=	M3m3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M{HyO2Z2dmO2aX;uJIF{e2G7		MXGzNEBucW6\|	MmjvSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKURESgRmQzKCh\|M{OgeI8hPDZyIHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wN\|I{KM7:TT6=	MoLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MW\GeY5kfGmxbjDhd5NigQ>?		NX3vV3VPOzBibXnudy=>	MnHlSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKURESgRmQyKCh2NDD0c{AyPjhiYX3pco8h[WOrZDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkCzPFgh\|ryPLh?=	MnjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MYHGeY5kfGmxbjDhd5NigQ>?			NGjzcZNDcW6maX7nJIFn\mmwaYT5JJRwKGKrb4Tpcplt[XSnZDDCVmQ{KEKGMjCoN\|A3KHSxIESxO{BidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkC0NFch\|ryPLh?=	NWfUbXFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M2LHbWZ2dmO2aX;uJIF{e2G7			M4XjNWJqdmSrbnegZYZncW6rdImgeI8h[mmxdHnufYxifGWmIFLSSFIhSkR{IDizOFkhfG9iNE[wJIFucW6xIHHjbYQhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDifUBjcW9vbHH5[ZIhcW62ZYLm[ZJwdWW2comgcYV1cG:mLDDL[EA:KDBwMES1OEDPxE1w	NVzpXmZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M1jvbGZ2dmO2aX;uJIF{e2G7			MVfCbY5lcW6pIHHm[olvcXS7IITvJIJqd3SrbonsZZRm\CCEUlS0JGJFOiBqM{OzJJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYomgZolwNWyjeXXyJIlvfGW{ZnXyc41mfHK7IH3leIhw\CxiS3SgQUAxNjB2N{[g{txONg>?	NUO2W4hpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MVzGeY5kfGmxbjDhd5NigQ>?		MoDtN\|AhdWmwcx?=	Mmm4SIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKUREKgRmQzKCh\|NEmgeI8hPDZyIHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wOFkzKM7:TT6=	NY\hNIdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NGS0RXVHfW6ldHnvckBie3OjeR?=		MmXKN\|AhdWmwcx?=	NEDyXHNFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEN{BDTDFiKEK0JJRwKDF2NDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFU{QSEQvF2u	NX3m[VI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MWHGeY5kfGmxbjDhd5NigQ>?		NFLvUJY{OCCvaX7z	M{jRemRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSyJGJFOSBqN{KgeI8hOjB3IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wOVY5KM7:TT6=	NUjhSY5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MWrGeY5kfGmxbjDhd5NigQ>?			MWHCbY5lcW6pIHHm[olvcXS7IITvJIJqd3SrbonsZZRm\CCEUlSzJGJFOSBqMkSgeI8hOTR2IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCkeTDibY8udGG7ZYKgbY51\XKoZYLvcYV1enlibXX0bI9lNCCNZDC9JFAvODZyNzFOwG0v	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
MV4-11	NW\lNFd[S3m2b4TvfIlkcXS7IHHzd4F6		M2nFeVQh\GG7cx?=	MkXCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGijcnLvdolv\yCPTFyxJIZ2e2mxbjDn[Y5mKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDRiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG\|c3H5MEBKSzVyIE2gNE4xQTNizszNMi=>	NYnvRlhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NYW2XW1bTnWwY4Tpc44h[XO\|YYm=		NVXhOphPOzBibXnudy=>	M3j2fWRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlS0JGJFOiBqM{OzJJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4xQTh2IN88UU4>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NEjYU3ZHfW6ldHnvckBie3OjeR?=			NULDOI95SmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFPCCEREGgLFQ1KHSxIEG2PEBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkC5PVQh\|ryPLh?=	M2G1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	NEn4R5BHfW6ldHnvckBie3OjeR?=		NIXxd\|U{OCCvaX7z	NIWwSoZFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEOEBDTDFiKES0JJRwKDF4ODDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4yPTZizszNMi=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	Ml7LSpVv[3Srb36gZZN{[Xl?			NUHPNoJoSmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOiCEREGgLFczKHSxIEKwOUBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkG1PUDPxE1w	M4CzclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
MOLM13	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=		M1zSRVQh\GG7cx?=	MnHnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUW9NVTF\|IHPlcIx{KGijcnLvdolv\yCPTFyxJIZ2e2mxbjDn[Y5mKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDRiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG\|c3H5MEBKSzVyIE2gNE4zPDFizszNMi=>	MnvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
BL21(DE3)	MXXGeY5kfGmxbjDhd5NigQ>?			NF7RSHNDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlv[WxiSHnzOk11[WepZXStRnJFPCCkcn;tc4RwdWGrbjCyJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGOxbYDleIVvfCCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCrc3;0bIVzdWGuIITpeJJifGmxbjDjZYxwemmvZYTyfUwhU2RiPTCwMlA3PSEQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN4N{WzPUc,OjZ\|Nke1N\|k9N2F-
BL21(DE3)	MVXGeY5kfGmxbjDhd5NigQ>?			NGfYe4NDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlv[WxiSHnzOk11[WepZXStRnJFPCCkcn;tc4RwdWGrbjCxJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGOxbYDleIVvfCCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCrc3;0bIVzdWGuIITpeJJifGmxbjDjZYxwemmvZYTyfUwhU2RiPTCwMlA6PSEQvF2u	M3f5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{[3OVM6Lz5{NkO2O\|U{QTxxYU6=
BL21(DE3)	MXnGeY5kfGmxbjDhd5NigQ>?			NIXvWZFDcW6maX7nJIFn\mmwaYT5JJRwKG[3bHygcIVv\3SqIF6teIVzdWmwYXygTIl{Pi22YXfn[YQuSlKGMjDido9ud2SxbXHpckAzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHPvcZBmfGWwdDDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV\|KTDj[YxteyCkeTDpd491cGW{bXHsJJRqfHKjdHnvckBk[Wyxcnnt[ZRzgSxiS3SgQUAxNjFizszNMi=>	MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|Nke1N\|koRjJ4M{[3OVM6RC:jPh?=
BL21(DE3)	MlHiSpVv[3Srb36gZZN{[Xl?			NXPMO3JSSmmwZHnu[{Bi\m[rbnn0fUB1dyCodXzsJIxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlNUKUREKgZpJwdW:mb33hbY4hOSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDjc41x\XSnboSgSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNiYomgbZNwfGincn3hcEB1cXS{YYTpc44h[2Gub4LpcYV1enluIFvkJF0hOC5{MzFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN4N{WzPUc,OjZ\|Nke1N\|k9N2F-
BL21(DE3)-R3-pRARE2	Mnz4SpVv[3Srb36gZZN{[Xl?			M3SwemlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTh[4dm\CCEUlS0JIJzd22xZH;tZYlvKDJiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSiGRUOpMXI{NXCUQWLFNkBk\WyuczDifUBHWkWWIHHzd4F6NCCLQ{WwJF0hOC5yM{[g{txONg>?	NELI[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkezNVQ6OCd-Mk[3N\|E1QTB:L3G+
BL21(DE3)-R3-pRARE2	NF\IemlHfW6ldHnvckBie3OjeR?=			MlTnTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmtVlMueFKDUlWyJINmdGy\|IHL5JGZTTVRiYYPzZZktKEmFNUCgQUAxNjB\|NjFOwG0v	MmP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
Rosetta2 DE3	NFHkdlVHfW6ldHnvckBie3OjeR?=		MoHMN\|AhdWmwcx?=	MXfJcohq[mm2aX;uJI9nKE[DTT3sZYJmdGWmIGrCRVI1QCCkaX7kbY5oKHSxIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhSlKGNDDido9ud2SxbXHpckAzKCh\|M{OgeI8hPDZyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkhTmyxdYLld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkCyN{DPxE1w	NUTEPVRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
Rosetta2 DE3	MmXJSpVv[3Srb36gZZN{[Xl?		NFj6bYk{OCCvaX7z	MXnJcohq[mm2aX;uJI9nKE[DTT3sZYJmdGWmIGrCRVI1QCCkaX7kbY5oKHSxIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhSlKGNDDido9ud2SxbXHpckAyKCh2NDD0c{AyPjhicnXzbYR2\XNrIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBHdG:3cnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDLbUA:KDBwMES2OEDPxE1w	NUfZfnZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
Rosetta2 DE3	NWT5c3F3TnWwY4Tpc44h[XO\|YYm=		M4XoUlMxKG2rboO=	NUTv[FhPUW6qaXLpeIlwdiCxZjDGRW0udGGkZXzl[EBbSkF{NEigZolv\GmwZzD0c{Bz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEirc{[teIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMjCoN\|M{KHSxIES2NEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB\|MDDtbY5{KGK7IF\sc5Vz\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjB5N{Wg{txONg>?	MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
MV4-11	MkL0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlnIOEBl[Xm\|	M2rVW2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWLUigZZN{[XluIFnDOVAhRSByLkC5N{DPxE1w	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3	MXXGeY5kfGmxbjDhd5NigQ>?		M1;uRlMxKG2rboO=	NWnBeHd5UW6qaXLpeIlwdiCxZjDGRW0udGGkZXzl[EBbSkF{NEigZolv\GmwZzD0c{Bz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEirc{[teIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMTCoOFQhfG9iMU[4JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHHmeIVzKDNyIH3pcpMh[nliRnzveZJme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3MDC9JFAvOTR3IN88UU4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
MOLM13	NI\td4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mm[4OEBl[Xm\|	NWWzZ\|dKT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OTUGzJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCZU2StPEBie3OjeTygTWM2OCB;IECuNlQyKM7:TT6=	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
TY82	M2rPOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NETQR2U4OiCqcoO=	NEf0flBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTZPFIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlIh\|ryPLh?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
MM1S	NH;aVmFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoO5O\|IhcHK\|	MoexRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPTUHTJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6yN{DPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
BL21 (DE3)-codon plus-RIL	NEe4SHFHfW6ldHnvckBie3OjeR?=		NVm3bpZwPCCqcoO=	M2PHZmlvcGmkaYTpc44hd2ZiSmGxMWZKXENiYnnu[Ilv\yC2bzDIbZM3NXSjZ3fl[EBDWkR2LVLENUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgLGRGOylvY3;kc44heGy3cz3STWwh[2WubIOgbY5kfWKjdHXkJIlvKGSjcnug[o9zKDRiaILzJIJ6KG[udX;y[ZNk\W6lZTDhcol{d3S{b4D5JIF{e2G7LDDJR\|UxKD1iMD6yOkDPxE1w	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OE[3NVgoRjJ6NUi2O\|E5RC:jPh?=
THP1	NIXlNY1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NHPPN2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlI6KM7:TT6=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl\|OUGyNUc,Ojh7M{mxNlE9N2F-
TY82	NXLoNnVYSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MkLxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCWWUiyJINmdGy\|LDDJR\|UxKD1iMD6zPUDPxE1w	NEL1VIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmzPVEzOSd-Mki5N\|kyOjF:L3G+
NALM16	NUTETYtLS3m2b4TvfIlkcXS7IHHzd4F6		MnzVOUBl[Xm\|	NEnIeo5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPSUyPMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBGSzVyIE2gNE4zPyEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
NALM6	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MXG1JIRigXN?	MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDORWxOPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPSCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkO5JO69VS5?	Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
697	M{X6NGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFLDV\|U2KGSjeYO=	NX\DSodWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hPjl5IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB3IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IEGuNVch\|ryPLh?=	M4LIS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
HD-MB03	NXXNR\|I2S3m2b4TvfIlkcXS7IHHzd4F6		NXX0dYZ1PSCmYYnz	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISE1OSjB\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB3IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IEOuOUDPxE1w	NXLIdoI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|AxOjRpPkK5NVcxODJ2PD;hQi=>
A673	NVj0e\|h1eUiWUzDhd5NigQ>?			NEe4UGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NWTDS2d6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NH\1OlJyUFSVIHHzd4F6			MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	Mmr5dWhVWyCjc4PhfS=>			M{O1PJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M1y0SJFJXFNiYYPzZZk>			NYHlRmRseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NUKxU4NrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NWXMVYF[eUiWUzDhd5NigQ>?			NH3zephyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MlfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NWjDOGtFeUiWUzDhd5NigQ>?			M{\2TZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	M33xfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NFuxVYVyUFSVIHHzd4F6			NXXyPI1reUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MnvBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NFHHOppyUFSVIHHzd4F6			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MX7xTHRUKGG\|c3H5			MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	M1W5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	M37OdZFJXFNiYYPzZZk>			NUDRe25GeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M1mzNJFJXFNiYYPzZZk>			M33pepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NYDoSWxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	M2LZUpFJXFNiYYPzZZk>			NH2wOppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	M4PWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MXrxTHRUKGG\|c3H5			NF6zb\|ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TY82	NFfGTldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{W2flczKGi{cx?=	NWXaWVhrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUXVgzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4{ODR\|IN88UU4>	MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N\|UoRjJ7NUK1OFM2RC:jPh?=
MM1S	MkjoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEXRS3Y4OiCqcoO=	MmDzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPTUHTJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6zOFkzKM7:TT6=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N\|U9N2F-
TY82	MmH5SpVv[3Srb36gZZN{[Xl?	M3XucVAvOiC2bzCxJJVO	NVfRV\|ZMOjRiaILz	MUDJcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gWHk5OiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ{1OgWNicILveIVqdiCneIDy[ZN{cW:wIHH0JFAvOiC2bzCxJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NGrtdmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
TY82	M2D1SGZ2dmO2aX;uJIF{e2G7	M{PNbFAvOiC2bzCxJJVO	MljKNlQhcHK\|	NWCwRolmUW6qaXLpeIlwdiCxZjDCVmQ1KGmwIHj1cYFvKFS\OEKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGNvTYnjJI1TVkFiZYjwdoV{e2mxbjDheEAxNjJidH:gNUB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nz	NX6zWlVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NlU1OzVpPkK5OVI2PDN3PD;hQi=>
TY82 or NCI-H1299	MUnGeY5kfGmxbjDhd5NigQ>?	MlXWNE4zKHSxIEGgeW0>	M4jud\|I1KGi{cx?=	MYDJcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gWHk5OiCxcjDOR2kuUDF{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFCGLVyxJJBzd3SnaX6g[ZhxemW\|c3nvckBifCByLkKgeI8hOSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M4K5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUK1OFM2Lz5{OUWyOVQ{PTxxYU6=
TY82 or NCI-H1299	MmrpSpVv[3Srb36gZZN{[Xl?	NELJUXgxNjJidH:gNUB2VQ>?	MlrrNlQhcHK\|	NXTRfXBWUW6qaXLpeIlwdiCxZjDCVmQ1KGmwIHj1cYFvKFS\OEKgc5IhVkOLLVixNlk6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDQSE1NOSCvUl7BJIV5eHKnc4Ppc44h[XRiMD6yJJRwKDFidV2gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>?	M4TKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUK1OFM2Lz5{OUWyOVQ{PTxxYU6=
C4-2B	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmLoPVYhcHK\|	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEN2LULCJINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCFZXzsMXRqfGW{IHfsc{Bz\WGpZX70JIJie2WmIHz1cYlv\XOlZX7j[UBie3OjeR?=	M{j5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
22Rv1	M{TjUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4q3Slk3KGi{cx?=	M{HlN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMkLSelEh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IFPlcIwuXGm2ZYKg[4xwKHKnYXflcpQh[mG\|ZXSgcJVucW6nc3PlcoNmKGG\|c3H5	MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
LNCAP	NV3OUVBxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MonEPVYhcHK\|	M1;hZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IFPlcIwuXGm2ZYKg[4xwKHKnYXflcpQh[mG\|ZXSgcJVucW6nc3PlcoNmKGG\|c3H5	NFnrWIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
HL60	Mlq2R5l1d3SxeHnjbZR6KGG\|c3H5			MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>?	Mn74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NUewPVkoRjJ7NkW3NFk6RC:jPh?=
Raji	NWHBPWxXTnWwY4Tpc44h[XO\|YYm=			NUH0Z4EzUW6qaXLpeIlwdiCxZjDCVmQ1NUKGMTDpckBpfW2jbjDSZYpqKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKE2\QzDn[Y5mKGW6cILld5Nqd25iYomgVGNTKG2ndHjv[EwhUUN3MDC9JFAvOTN{IN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3N{C5PUc,Ojl4NUewPVk9N2F-
LNCAP	NUXxW\|EySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MkfRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOTlPBVEBk\WyuczygTWM2OCB;IECuN\|U3PSEQvF2u	M4LidFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
MV411	NUfpWpliS3m2b4TvfIlkcXS7IHHzd4F6		M4[0SVczKGi{cx?=	MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQyOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvQCEQvF2u	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ4OEewNkc,OzB{Nki3NFI9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Growth inhibition assay	Cell viability ; PubMed: 26840085 Oncotarget A., B. and C. Dose response curves of MPNST-derived cell lines treated with three bromodomain inhibitors: JQ1, OTX015 and I-BET-762.	26840085

In vivo

I-BET-762 confers protection against lipopolysaccharide-induced endotoxic shock and bacteria induced sepsisa. Single dose of I-BET applied at 1.5 h after LPS injection cures the mice. Twice-daily injections of I-BET for 2 days protects mice against death caused by sepsis. ^[1] Limited treatment with I-BET-762 exclusively during early priming inhibited the ability of Th1-differentiated 2D2 T cells to induce neuroinflammation in a mouse model of experimental autoimmune encephalomyelitis (EAE). ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Fluorescence resonance energy transfer (FRET) titrations: Fluorescence resonance energy transfer (FRET) titrations. I-BET is titrated against BRD2 (200 nM), BRD3 (100 nM) and BRD4 (50 nM) in 50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM CHAPS in the presence of tetra-acetylated Histone H4 peptide (200 nM). After equilibrating for 1 hour, the bromodomain protein : peptide interaction is detected using FRET following the addition of 2nM Europium cryptate labelled streptavidin and 10 nM XL-665-labelled anti-6His antibody in assay buffer containing 0.05% (v/v) BSA and 400 mM KF. Plates are read using an Envision Plate reader (excitation 320 nm, emission 615 nm and 665 nm).
Cell Research:^[2]	- Collapse Cell lines: CD4⁺ T cells Concentrations: ~500 nM Incubation Time: 60–72 h Method: CD4⁺ T cells are isolated from lymph nodes and spleens of 10- to 12-wk old mice and activated with plate bound anti-CD3 and anti-CD28 antibodies in the presence of indicated cytokines. I-BET-762 compounds is included during the 60–72 h of initial activation. Over the course of 5 d of T-cell culture and expansion, the compounds is diluted 12-fold relative to the starting concentrations. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse Dosages: 30 mg/kg Administration: i.v. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (198.15 mM)
	Ethanol	42 mg/mL warmed (99.07 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Molibresib (I-BET-762) SDF

Molecular Weight	423.9
Formula	C₂₂H₂₂ClN₅O₂
CAS No.	1260907-17-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	GSK525762, GSK525762A
Smiles	CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03266159	Withdrawn	Drug: GSK525762 Besylate tablets\|Drug: Trametinib tablets	Solid Tumours	GlaxoSmithKline	November 27 2017	Phase 2
NCT02964507	Active not recruiting	Drug: GSK525762\|Drug: Placebo\|Drug: Fulvestrant	Neoplasms	GlaxoSmithKline	February 2 2017	Phase 2
NCT01943851	Completed	Drug: GSK525762	Neoplasms	GlaxoSmithKline	May 14 2014	Phase 2
NCT01587703	Completed	Drug: GSK525762	Carcinoma Midline	GlaxoSmithKline	March 28 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Selective BET Inhibitor

PFI-1 (PF-6405761) : BRD4-selective, IC50=0.22 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

Bromosporine : Broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

Molibresib (I-BET-762)